Market Overview

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Prothena Corporation Investors


Prongay & Murray LLP
("GPM") announces an investigation on
behalf of Prothena Corporation ("Prothena" or the "Company") (NASDAQ: PRTA)
investors concerning the Company and its officers' possible violations
of federal securities laws. To obtain information or aid in the
investigation, please visit the Prothena investigation page on our
website at

On October 15, 2015, Prothena disclosed its late-stage Phase 2b "PRONTO"
study and expansion of its Phase 1/2 clinical trial for the antibody
NEOD001. On April 23, 2018, Prothena announced it was ending development
of NEOD001 after its Phase 2b PRONTO trial failed to reach either its
primary or secondary endpoints. On this news, shares of Prothena fell
$25.34, or nearly 69%, to close at $11.50 on April 23, 2018, thereby
injuring investors.

If you purchased Prothena securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to,
or visit our website at
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at